• Blog
  • Plasmid DNA Manufacturing Market Report

    Plasmid DNA Manufacturing Market Report

    Plasmid DNA Manufacturing Market Report
    Report code - SR1415 Published On : Dec,2021 No. of Pages: 110
    Get Free Sample |
    Plasmid DNA Manufacturing Market Size, Share, Trend, Forecast, Competitive Analysis, and G See more...

    Impact of COVID-19 on Plasmid DNA Manufacturing Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Plasmid DNA Manufacturing Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Highlights

    Plasmid DNA plays a vital role in the modern healthcare industry. It can be utilized directly for therapeutic purposes, such as gene therapy or the production of vaccine antigens, or indirectly for a variety of research purposes such as gene mapping, gene cloning, etc. for preventing diseases like cystic fibrosis or Huntington’s disease. These include the usage of plasmid DNA as a vital starting material for temporary transfection to build viral-vector constructions like lentivirus or Adeno-associated virus (AAV) as well as transitory proteins in development like monoclonal antibodies. Gene therapy is a rapidly growing field in medicine that promises novel therapies for individuals suffering from a variety of ailments. 

    Due to the COVID-19 pandemic, manufacturers of plasmid DNA are experiencing substantial challenges on multiple fronts. The supply of raw materials for producing medication formulations is a serious concern because of transportation facility inconsistencies. Furthermore, due to an increase in the number of patients suffering from COVID-19 and other life-threatening conditions, distributors are seeing erratic demand for health-related products from retailers.

    The global biopharmaceutical industry has seen a growth in the plasmid DNA manufacturing business. The rising use of plasmid DNA in the biopharmaceutical industry for producing vaccines and treatments for a variety of ailments is driving up demand for plasmid DNA. Overall, the plasmid DNA manufacturing market is likely to grow at a promising CAGR of 17.2% in the long run to reach US$ 1.5 Billion in 2027.

    Segments' Analysis

    Based on the application type, the plasmid DNA manufacturing market is segmented as gene therapy, DNA vaccines, immunotherapy, and others. Gene therapy is projected to remain the dominant application of the market over the next five years owing to the increasing use of gene therapy to treat a variety of viral and genetic diseases. It is also widely used to diagnose disorders in patients, hence, increasing demand for the treatment. 

    Based on the product type, the market is segmented as viral vectors, plasmid DNA, non-viral, electroporation, lipid/polymer, nanoparticles, and others. The viral vector is expected to remain the dominant as well as the fastest-growing product type in the market during the forecast period. The viral vector is already in high demand in the manufacturing of vaccines, cell treatments, and gene therapies all around the world. The COVID-19 pandemic contributed to the increased need for vaccine manufacture. Increasing preference for viral vectors for vaccines productions and various gene and immunotherapy applications is the major driving factor for the segment in the coming years.

    In terms of regions, North America is expected to remain the largest market for plasmid DNA manufacturing market during the forecast period. The rising number of contract manufacturers in the region is a result of increased investments in the development of new biopharmaceutical drugs. Furthermore, the USA holds the most intellectual property copyrights for most newly developed treatments. A key factor that is driving the demand for the plasmid DNA manufacturing market in North America is the increased adoption rate of modern healthcare services along with the growing preference for gene and cell therapies.

    Key Players

    The following are the key players in the plasmid DNA manufacturing market:

    • Aldevron, LLC
    • Cell and Gene Therapy Catapult
    • Cobra Biologics and Pharmaceutical Services
    • Delphi Genetics
    • Eurofins Genomics
    • Kaneka Corporation
    • Nature Technology Corporation
    • PlasmidFactory GmbH and Co. KG
    • VGXI, Inc.
    • Waisman Biomanufacturing

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s plasmid DNA manufacturing market realities and future market possibilities for the forecast period of 2022 to 2027. The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market. The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis.
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Market trend and forecast analysis.
    • Market segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    The plasmid DNA manufacturing market is segmented into the following categories. 

    Plasmid DNA Manufacturing Market, by Product Type

    • Viral Vectors (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Plasmid DNA (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Non-Viral (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Electroporation (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Lipid/Polymer (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Nanoparticles (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Others (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)

    Plasmid DNA Manufacturing Market, by Application

    • Gene Therapy (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • DNA Vaccines (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Immunotherapy (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Others (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)

    Plasmid DNA Manufacturing Market, by Disease Type

    • Infectious Disease (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Genetic Disorder (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)
    • Cancer (Regional Analysis: North America, Europe, Asia-Pacific, and RoW)

    Plasmid DNA Manufacturing Market, by Region

    • North America (Country Analysis: USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, the UK, Russia, and Rest of Europe)
    • Asia-Pacific (Country Analysis: Japan, China, India, and Rest of Asia-Pacific)
    • Rest of the World (Country Analysis: Brazil, The UAE, and Others)

    Report Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com

    Frequently Asked Questions (FAQs)

    The plasmid DNA manufacturing market is estimated to grow at a CAGR of 17.2% by 2027.

    Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, LLC, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult are the leading players in the plasmid DNA manufacturing market.

    North America is estimated to remain dominant in the plasmid DNA manufacturing market in the foreseen future.

    //